Rajat Srivastava
| Scheme | Fund house | Role, as filed | Since | Read |
|---|---|---|---|---|
| Tata India Pharma & Healthcare Fund | Tata Mutual Fund | — | — | 29 Sep 2026 |
From each scheme's summary document on AMFI's site (scheme details), read on the date shown. A scheme can have several managers; each change below counts for every manager named on it.
| Stock | Schemes | Net, share count × price |
|---|---|---|
| GLAXO | 1 | −₹39.9 cr |
| CONCORDBIO | 1 | −₹29.5 cr |
| DIVISLAB | 1 | −₹26.7 cr |
| NEULANDLAB | 1 | −₹19.3 cr |
| BASF | 1 | −₹14.9 cr |
| SAILIFE | 1 | −₹11.7 cr |
| MEDANTA | 1 | −₹8.3 cr |
| LALPATHLAB | 1 | −₹8.1 cr |
| JUBLPHARMA | 1 | −₹8.0 cr |
| SANOFI | 1 | −₹3.5 cr |
| GILLETTE | 1 | −₹0.04 cr |
Each scheme's change in shares from the month before, at its month-end price, summed over this manager's schemes; a split or bonus (ISIN changed) is left out. Source: the AMC monthly portfolios.